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ABSTRACT  
The use of mesenchymal stem cells (MSCs) for tissue regeneration is often hampered by modest 
engraftment in host tissue. This study was designed to quantitatively compare MSCs engraftment 
rates after delivery using a polysaccharide-based porous scaffold or endocardial (EC) injection in a rat 
myocardial infarction model. Cellular engraftment was measured by quantitative RT-PCR using 
MSCs previously transduced with a lentiviral vector that expresses GFP. The use of a scaffold 
promoted local cellular engraftment and survival. The number of residual GFP+ cells was greater with 
the scaffold than after EC injection (9.7% vs 5.1% at 1 month and 16.3% vs 6.1% at 2 months, 
respectively (n=5)). This concurred with a slight increase in mRNA VEGF level in the scaffold group 
(p<0.05). Clusters of GFP+ cells were detected in the peri-infarct area, mainly phenotypically 
consistent with immature MSCs. Functional assessment by echocardiography at 2 months post infarct 
also showed a trend towards a lower left ventricular dilatation and a reduced fibrosis in the scaffold 
group in comparison to direct injection group (n=10). These findings demonstrate that using a porous 
biodegradable scaffold is a promising method to improve cell delivery and engraftment into damaged 
myocardium. 
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INTRODUCTION 
Ischemic injury induces a heart failure as the end of pathological remodelling of the 
myocardium. Conventional treatments do not replace lost cardiomyocytes, opening the way to new 
approaches such as genes, growth factors, and cell-based therapies.1 Cardiac cell therapy has evolved 
quickly and a variety of candidate cells, mainly skeletal myoblasts, hematopoietic and more recently 
mesenchymal stem cells (MSCs) have been tested to repair damaged hearts. MSCs are an attractive 
cell source for therapeutic applications, particularly as they can be easily cultured and release a large 
array of soluble growths factors and cytokines underlying some paracrine effects.2 Despite promising 
experimental studies and early clinical trials, up to now, progress in cell therapy is hampered by sub-
optimal engraftment of donor cells into the myocardium.3 Typical approaches to deliver MSCs to 
infarcted myocardium are intravenous (IV), intracoronary (IC) and endocardial (EC) injection.4 In a 
quantitative study evaluating these three methods for MSC delivery in a porcine delivery, Freyman et 
al. reported an increased, but still limited, engraftment of MSCs after IC or EC injection when 
compared with IV infusion (3%, 6% and 0 %, respectively).4 EC injection offers direct localization of 
cells to the injured area, but engraftment is limited by leakage out of the injection sites. IC delivery 
was associated with a high incidence of decreased coronary blood flow. More recently, in a canine 
acute myocardial ischemia model, Perin et al. found an increased vascularity and greater functional 
improvement with EC delivery than IC delivery of MSCs.5  
The approach to improve exogenous cell delivery to tissue, whatever the cell source, is of 
major clinical importance and has stimulated further investigation on the use of bioengineered 
scaffolds as cell delivery vehicles.6 One of the challenges involves the development of optimized 
biocompatible materials functioning as synthetic analogs of the extracellular matrix, that would both 
provide a substrate for transplanted cells and promote cell engraftment.7 Many materials have been 
used including polyglycolic acid (PGA), collagen gel, alginate and gelatin mesh. In this context, we 
previously described the preparation of a polysaccharide-based scaffold as a novel biomaterial for 
cardiovascular engineering.8 Naturally-derived polysaccharides are hydrophilic, biodegradable, 
biocompatible and can form highly hydrated gels that could mimick the extracellular matrix. 9  
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Naturally-derived polysaccharides are hydrophilic, biodegradable, biocompatible and can form highly 
hydrated gels that could mimick the extracellular matrix.9  
 In the present study, we used a rat model of acute myocardial infarct to examine MSCs 
engraftment in infarcted tissue using this polysaccharide-based porous scaffold in comparison with 
endocardial injection. Syngeneic MSCs stably transduced with a lentiviral vector allowed accurate in 
vivo assessment of cell retention after cardiac delivery. The effects on cardiac remodelling and 
function were then evaluated. 
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MATERIAL AND METHODS 
Culture, characterization and preparation of MSCs 
MSCs were obtained from the bone marrow of syngeneic adult Lewis rats (Janvier). Briefly, 
cells were collected by flushing femurs and expanded in DMEM (Gibco) supplemented with 1% 
penicillin/streptomycin and 10% fetal bovine serum at 37°C in a 5% CO2 atmosphere. Cells were 
subcultured every 4-7 days. 
Characterization of rat MSCs was performed by flow cytometry analysis with a phycoerythrin 
(PE)-conjugated anti-human CD45 (Immunotech) antibody (MoAb) (BioLegend) and with fluorescein 
isothiocyanate (FITC)-conjugated anti-CD90 (Becton Dickinson), anti-CD106 monoclonal and anti-
CD29 MoAbs (BioLegend). MSCs were also characterized by their capacity to differentiate along 
adipogenic, chondrogenic, and osteogenic lineages.10 The ability of MSCS to differentiate towards 
cardiac lineage is controversial. We did not obtain any cardiac differentiation from rat MSCs during 
our in vitro culture. 
 
 
Scaffold preparation 
 Polysaccharide-based scaffolds were prepared using a mixture of pullulan (Hayashibara) and 
dextran (Pharmacia), and sodium carbonate was added as a porogen agent.11 Chemical cross-linking 
was carried out using trisodium trimetaphosphate STMP (Sigma) under alkaline conditions as 
described.12 After a freeze-drying step, a circular punch was used to cut 6mm diameter and 1mm 
thickness round-shaped porous scaffolds. Scaffolds were observed with Environmental Scanning 
Electron Microscopy (ESEM) using an ESEM-FEG (Philips XL 30, Netherlands) with an accelerating 
voltage of 15 kV at a pressure of 4 torrs. Fluorescent scaffolds were prepared by adding 1% of 
Fluorescein-IsoThioCyanate-dextran (Sigma) before cross-linking for confocal miscroscopy 
observation. Optical sections were acquired using a Zeiss LSM 510 confocal microscope (Carl Zeiss, 
Oberkochen, Germany), equipped with a 10x Plan-NeoFluar objective lens (numerical aperture of 0.3) 
(Carl Zeiss). FITC-dextran was excited at 488 nm with an argon laser and its fluorescent emission was 
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selected by a 505-530 nm bandpass filter. Scaffolds were submitted to UV prior to cell seeding. Cell 
loading was performed after cell trypsinization by rehydration of a dried scaffold with 20μL of cell 
suspension. In a first set of in vitro experiments, optimal cell density was determined using from 
2x104 to 106 cells/scaffold, with scaffold size ranging from 2mm to 10mm in diameter. A metabolic 
MTT assay was performed 1 day later, by incubating seeded scaffolds with 0.5 mg/mL of MTT (3-
(4,5-dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide, Sigma) for 3 hours at 37°C. Resulting 
formazan crystals were solubilized in 0.5 mL of DMSO and absorbance was recorded at 570 nm with 
a microplate reader. Non-cellularized porous scaffolds were used as controls. Cell viability was 
assessed with a Live/dead kit (Invitrogen). Briefly, cellularized scaffolds were incubated with 4 µM 
calcein AM and 2 µM ethidium homodimer-1 solution (Invitrogen) for 1 hour at 37°C. Cellularized 
scaffolds were then observed with a Zeiss LSM 510 confocal microscope using a standard fluorescein 
bandpass filter for calcein and a propidium iodide filter for EthD-1.  
Prior to in vivo administration, 106 cells were seeded on a 6mm porous scaffold with 20μL of cell 
suspension; thirty minutes after, once cells attached, scaffolds were placed in 1ml culture medium for 
complete rehydratation. 
 
Animal study 
Both the procedure and the animal treatment complied with the Principles of Laboratory 
Animal Care formulated by the National Society for Medical Research. The studies were carried out 
under authorization 006235 of the Ministere de l’Agriculture, France. 
In a first set of 3 experiments, migration from scaffold to cardiac tissue was evaluated in 
healthy myocardium. Afterward, male syngenic Lewis rats were submitted to the ligation of the 
descending anterior left coronary artery. Fifteen minutes after infarct, rats received 1x106 MSCs 
according to the following procedures: the endocardial (EC) group received 5 myocardial injections of 
MSCs suspended in 20µL of culture medium in the peri-infarct and infarct zones. In the patch group, 
the cellularized scaffold was covered by a clinical polytetrafluoroethylene (PTFE) membrane 
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(Pericardial, St Jude Medical) that was glued onto the infarcted area. For the control scaffold group, 
non-cellularized scaffolds were implanted in the same conditions.  
 
Determination of cellular engraftment  
For assessment of cell retention, Lewis rat MSCs were transduced using a lentiviral vectors 
construct consisting in a dual-promoter that included GFP under the regulation of the human EF1 
promoter (EF1GFP) and PAC under the human puromycin resistance gene (puromycin-N-
acetyltransferase; PAC) promoter. Evaluation of the transduction efficiency was based on the 
percentage of GFP+ cells. Three syngeneic lines of transfected MSC were thus obtained and mixed for 
in vivo administration (passages 4 to 9). Animals were randomly assigned to the delivery method, 
scaffold or EC group. Engraftment was evaluated 1 and 2 months following GFP+ MSC delivery in 
the 2 groups (n=5 per group for each time point). 
GFP+ cell quantification in cardiac tissue was performed using molecular analysis of gene 
expression by quantitative PCR. The heart was removed and infarct region, border zone and large area 
of peri-infarct healthy myocardium were cut into slices <0.5mm thick and immediately submerged in 
RNA later stabilization reagent (Sigma, France). A reference curve was established on the basis of the 
GFP expression level from defined numbers of GFP+ cells (triplicate samples from 10x103 to 1x106 
GFP+ cells per sample) used as calibrator. Quantitative PCR was performed on a 7500 Real Time 
PCR System (Applied Biosystems) with standard cycling conditions. GFP expression levels were 
normalized relative to the expression of rat HPRT, UBC and Ywhaz.  The number of residual GFP+ 
cells after EC injection or scaffold administration was estimated by report to the reference curve. 
 
Histology, immunofluorescence and immunohistochemistry analysis 
Analysis were performed after administration of GFP+ MSCs or MSCs double labelled with 
thymidine analog 5-bromo-2’-deoxyuridine BrdU (10µM for 24 hours) and with a fluorescent dye 
(PKH26, Sigma) (n=3, each condition). 
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Left ventricles were harvested, fixed in buffered formalin and embedded in paraffin for 
histological stains or in OCT for cryosections and immunohistochemical study. Histological sections 
were stained with hematoxylin and eosin (H/E) and with Sirius red stain (0.1% in saturated picric acid 
solution). Fibrosis area and total ventricular area (LV) were quantified by histomorphometric 
measurement on Sirius red stained sections with Histolab software (Microvision). Fibrosis percentage 
was calculated as: (fibrosis area/total LV area) × 100. 
Direct observation of PKH-labelled cells in myocardial tissue was performed on cryosections.  
Immunostaining of myocardial sections was performed using the primary antibodies, anti cardiac 
sarcomeric -actinin (Sigma), anti-connexin-43 (Dako), anti-smooth muscle actin (Dako), anti-CD31 
(Dako) and anti-GFP (Torrey Pines), secondary Alexa fluor goat anti-mouse 488 and 532 antibodies, 
all from Molecular Probes (Invitrogen) using a double-labelling technique. Immunostaining of BrdU-
positive cells was performed by indirect immunohistochemistry with anti-BrdU mouse antibody 
(Calbiochem) and DAB staining. Sections were counterstained with haematoxylin before mounting. 
 
Molecular analysis of gene expression by quantitative reverse transcription polymerase chain 
reaction (RT-PCR)  
MMP-2, MMP-9 and VEGF expression were measured on infarcted heart administered with MSCs 
using scaffold or EC injection, 1 and 2 months after infarct, in comparison with control animals 
submitted to infarct without cell administration. Immediately after sacrifice, samples were fixed in 
RNA stabilization reagent (RNA Later, Sigma). All primers were designed using intron-flanking 
method. Quantitative PCR was performed on a 7500 Real Time PCR System (Applied Biosystems) 
with standard cycling conditions. For housekeeping gene selection, the stability of various reference 
genes was investigated from different samples of rat infarcted hearts. The expression stability of 7 
commonly used reference housekeeping genes (GAPDH, 18S, ActB, CycA HPRT, UBCand 
YWHAZ) was analyzed using geNorm and expression stability was determined by the Genorm 
program. HPRT, UBC and YWHAZ were identified as most stable genes. Then, gene expression 
levels were normalized relatively to the expression of rat HPRT, UBC and Ywhaz. Quantification was 
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done with the Pfaffl’s method.13 Relative expression ratios were calculated by reporting values to 
those of the control animals. 
 
Echocardiographic and catheterization protocols 
For determination of cardiac function related to MSC delivery, non transduced MSCs were 
used. Animals were randomly assigned to the delivery method, either control, scaffold or EC group. 
All cardiac echocardiograms were recorded using an Acuson 128XP (Acuson corporation, Mountain 
View, California, USA) utilizing a 7-10Mhz transducer. The heart was first imaged in two-
dimensional mode in the parasternal long axis and short axis views, to position the M mode cursor 
perpendicular to the interventricular septum and left ventricular posterior wall. Then, M mode images 
were obtained at a 100 mm/sec speed. At least 3 measurements of LV end-diastolic (LVEDD) and 
end-systolic diameters (LVESD) were selected and averaged from each animal and the analysis of 
contractile function was derived from the LV fractional shortening fraction (LVFS): (LVEDD-
LVESD/LVEDD x 100). The echocardiographic examination was performed 7 days and 2 months 
after myocardial infarction by a blinded observer.  
 
Statistics 
All parameters were expressed as mean values ± standard deviation, except for engraftment 
results expressed as median values. A t-test was performed on fibrosis and mRNA data, a one way 
ANOVA test was performed on echocardiographic data and a two-way ANOVA was performed on 
engraftment data. Statistical significance level was set at 0.05. 
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RESULTS 
Cellularized scaffold for implantation 
We first examined the optimal conditions of MSCs seeding on the scaffold. Scaffolds from 
2 mm to 50 mm in diameter could easily be obtained and a 6 mm diameter porous scaffold, suitable 
for the size of rat hearts, was chosen (Fig. 1A). Porosity of scaffolds was observed with 
Environmental Scanning Electron Microscopy (Fig. 1B). The use of FITC-labelled dextran into 
polysaccharide scaffolds allowed confocal laser scanning microscopy observation of the inner 
structure of hydrated scaffolds. A typical single optical slice of a porous scaffold is shown on Fig. 1C. 
A mean pore size of 195 µm and a porosity of 41% were calculated. Cells infiltrated very quickly 
(<1min) within the scaffold porous structure like in a sponge, and the maximum volume contained 
was 15 µL. Using a metabolic MTT assay at day 1, we confirmed that 2x104 to 106 cells/scaffold 
could be seeded into 6 mm porous scaffold. Absorbance data as a function of the initial cell number is 
shown on Fig. 1D. Cells within the transparent scaffold could be observed with light microscopy as 
cell clusters (Fig. 1E).  Cell viability at day 1 was demonstrated with a live & dead assay (Fig. 1F). 
A first series of experiments was conducted with FITC-labelled non-cellularized scaffolds to 
determine the in vivo fate of porous scaffold in rat cardiac tissue (n=2). One month after implantation, 
scaffold was found intact on normal cardiac tissue (Fig. 2A, scaffold stained with alcian blue dye for 
imaging purposes), as confirmed by fluorescent microscopic observation of heart sections showing 
cardiac tissue green autofluorescence and FITC-labelled scaffold (Fig. 2B). In contrast, the scaffold 
on infarcted cardiac tissue was progressively degraded after implantation and only some remnants of 
the FITC-scaffold were seen embedded or integrated into the adjacent tissue on infarcted heart 
sections at 1 month (Fig. 2 C, D). 
 
Engraftment of MSC  
Typical MSCs were obtained and characterized by their spindle shaped morphology (Fig. 3A) 
and a CD45-CD90+, CD45-CD29+ and CD45-CD106+ phenotypic profile. From the third passage, 
CD45-CD90+ cells represented 93±3 % of the cultured cells (Fig. 3B). Additionally, under appropriate 
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inducing in vitro conditions, rat MSCs could display osteogenic, chondrogenic and adipogenic 
differentiation (Fig. 3C).  
Quantification of cell engraftment into the infarcted heart was performed using MSCs 
transduced with a lentiviral vector that expresses eGFP (Fig. 3D). The transduction efficiency of 
MSCs assessed by FACS as a percentage of GFP+ cells reached 98.8±2.5% (n=3). The number of 
residual eGFP+ cells was estimated by quantitative RT-PCR, after calibration with defined numbers of 
sorted eGFP+ MSCs (Fig. 3E). One month after administration of 1x106 eGFP+ MSCs, the median 
number of eGFP+ cells in the myocardium was greater after administration using scaffold than 
following EC injection with respectively 9.7% and 5.1% of the administered cells in the myocardium 
(Table 1). Engraftment was confirmed at 2 months. The median number of eGFP+ cells in the scaffold 
group and EC group represented 16% and 6.1% of the initial administered cells, respectively (n=5). 
 
MSC localization  
We then examined the ability of MSCs to migrate from the scaffold to the targeted tissue. 
MSCs localization was examined using eGFP+ cells or cells double-labelled with a fluorescent dye 
PKH26 and BrdU (n=3). When cellularized scaffolds were implemented on healthy myocardium, no 
labelled cells were detected in cardiac tissue. On the contrary, one month after implantation of 
cellularized scaffold on injured myocardium (Fig. 4A), immunofluorescence staining detected 
numerous PKH-labelled cells in the thin peri-infarcted cardiac tissue (Fig. 4B); some BrdU-positive 
MSCs were also observed in the same border area (Fig. 4C). This suggested the influence of attractive 
signals from infarcted area to induce cells moving from the implanted scaffold towards the targeted 
area (Fig. 4D). These data were confirmed using eGFP+ cells. In animals having MSCs implemented 
on scaffold, clusters of GFP+ cells were clearly detected in the peri-infarct area and in bordering 
healthy myocardium, one month (n=3) and two months (n=3) post infarct (Fig. 4E) but no GFP+ cells 
were detected within the infarct area. Most of the cells weakly co-expressed the CD106 marker 
indicating that the infused cells remained mainly phenotypically consistent with immature MSC cells 
(data not shown). Nevertheless, few cells expressed the cardiac tissue-specific marker, -actinin 
(Fig. 4E) and connexin 43 (data not shown).  
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Ventricular remodelling and biochemical modifications after MSC delivery using scaffold or EC 
injection 
It is believed that MSCs sustain the heart repair predominantly by facilitating endogenous 
processes, through paracrine effect particularly on scar formation and neovascularization. 
Haematoxylin and eosin (Fig. 5A, top row) and sirius red (Fig. 5A, bottom row) staining in 
histological heart sections were examined in animals having received cellularized scaffold or EC 
injection. Sirius red staining indicated collagen production into the infarcted area related to fibrosis. 
Quantitative measurement of fibrosis area on cardiac sections showed a trend, but not reaching 
significance, towards the reduction of fibrosis in the scaffold group compared to EC group (12±1% 
versus 16±3%, respectively) (Fig. 5B).  
We also measured the local production of MMP-2 and MMP-9 using qRT-PCR. MMP-2 and 
MMP-9 mRNA per milligram of infarcted hearts were similar 1 and 2 months following MSC 
administration, whatever the delivery condition (not shown). In contrast, VEGF mRNA level was 
significantly higher 2 months after administration in the scaffold group (Fig. 5C, bottom row; 
p<0.05). 
 
Echocardiographic and catheterism studies  
Functional assessment by echocardiography was performed 7 days and 2 months after 
myocardial infarction and cardiac graft implantation. At the baseline (7th post-operative day) 
LVEDD, LVESD, and LVFS were similar in both EC (respectively 7.0±1; 5.5±1; 21.8±6.7; n=9) and 
scaffold groups (respectively 7.4±1.8; 5.4±1.8; 27±9.2; n=9) as in the control group having received 
non cellularized scaffolds (respectively 7.3±1.2; 5.2±1.4; 30.5±9.9; n=9). Progressive left ventricular 
dilatation and deterioration of LVFS were observed in the control group at 2 months. On the contrary, 
there was a trend towards a higher LVFS and a lower LVESD in the cellularized scaffold group at 
2 months (Fig. 6).  
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DISCUSSION 
The approach to administer stem cells for cell therapy is mainly dependent of our ability to safely 
ensure sufficient delivery of cells within the target tissue and adequate local engraftment and function 
at this site. Different delivery strategies are required with regard to delivered cell types. For cardiac 
tissue, the intramyocardial route is suited to large, adherent cells and has been safely used for MSC 
infusion but suffers of a low engraftment rate. The potential interest of scaffolds in cardiac cell 
therapy is increasingly investigated to repair damaged tissue.14, 15 The use of cells in combination with 
appropriate scaffold should provide not only a physical support for cell orientation and proliferation 
but also molecular cues to direct cell survival, cell cycle progression, and the expression of different 
phenotypes.16 In this context, cell-seeded biocompatible cardiac patches could be considered as a 
promising approach. This study was designed to evaluate quantitatively MSC delivery in ischemic 
myocardium using a 3D scaffold in comparison with endocardial injection. Using a novel chemical 
cross-linking process combined with a porogen agent, polysaccharide-based porous scaffolds were 
prepared. MSCs were seeded into this porous scaffold that supports rapid integration of seeded cells. 
The hydrogel structure would allow exchange of oxygen, nutrients, and metabolites inside the porous 
scaffold, as well as the diffusion of cells. We found that homing of MSCs from the scaffold to 
myocardium required a signal such as infarct remodelling. After 30 days, cell delivery was associated 
with a greater number of engrafted cells when compared to EC delivery, with about 10% of the initial 
seeded cells present in the scaffold group, in comparison with 5% following EC administration. This 
concurred with the MSC engraftment rate previously reported by Freyman et al after EC delivery in a 
porcine myocardial infarction model.4 Differents factors could contribute to the improvement of cell 
delivery after implantation using a porous scaffold. A scaffold would provide a cell-friendly micro-
environment as well as a substrate for the transplanted cells that would prevent cell loss.17 It could 
also act as a mechanical support to enhance cell survival and cell proliferation. Indeed we observed an 
increase in GFP+ cell number from 1 month to 2 months after implantation, although this increase 
was not statistically significant. This suggests that a slight proliferation of implanted MSCs occurred. 
Even if the mechanism of cardiovascular repair from adult stem cells remains highly 
unknown, it is believed that MSCs act through paracrine actions. In agreement, a significant, despite 
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modest, difference in the mRNA level of VEGF between scaffold and EC group was achieved here at 
2 months, although no improved vascularization was evidenced (data not shown).  
Quantitative analysis of engrafted cells was performed using GFP+ transgenic cells. In 
comparison with engraftment assessment using immunohistochemical analysis that samples only a 
small fraction of the myocardium, this method enables the quantification of a low number of residual 
cells and their accurate detection through the entire myocardium. To our knowledge, this is the first 
time that cellular engraftment and survival in injured myocardium were measured by quantitative RT-
PCR. Internalized iridium technique, as performed by Freyman et al., offers quite similar interest.4 
Overestimation linked to non specific labelling of macrophages after phagocytosis of dead cells can 
be excluded with this method. In contrast, underestimation could be related to a potential immune 
reaction to GFP+ cells or to silencing of the GFP reporter gene during the process of differentiation, 
although these risks are not usually expected.18, 19  The relationship between GFP quantification by 
RT-PCR and cell number was thus determined by analyzing heart samples with known number of 
cells.  
Some experimental studies in large animal models and early clinical trial support the concept 
that MSCs improve heart function following myocardial infarction. Our seeded scaffold group 
demonstrated a trend towards an improvement of ventricular functions and fibrosis size. To expect 
better clinical effects, the number of seeded cells should be considered. Pouzet et al. have shown that 
there was a linear relationship between efficacy of functional improvement and the number of injected 
cells.20 A recent study in a large animal model revealed evidence of a dose-response effect to the MSC 
therapy following surgical injection and only a high dose of 200x106 MSCs reduced infarct size.21 
MSC delivery using the EC method is limited by the adverse events reported with high cell 
concentration and injection volume of 0.3 mL. In contrast, the initial number of cells can be easily 
increased using larger scaffolds; large porous scaffolds (2 cm in diameter) containing 200x106 
autologous bone marrow derived MSCs are currently implanted in a pig model of myocardial infarct. 
We are also conducting a dose-effect study with GFP+ cells to evaluate the relative contribution of cell 
engraftment to functional recovery. At the moment, limited functional data with GFP labelled cells 
suggested that a residual number of 3x105 MSC could sustained a regenerative effect. 
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PTFE membrane could be also involved in the lack of significant benefit in terms of 
functional improvement in animal receiving cellularized scaffold maintained using this membrane. 
Significant foreign body reaction and undesirable fibrous membrane with fibroblast proliferation has 
been reported using PTFE membrane; 22, 23 we observed by ourselves that membrane alone altered the 
epicardial anatomy. Control groups did not include the use of the PTFE membrane. At the time of the 
study, the membrane was the more convenient system to maintain our scaffold on the myocardial 
injury but we are now considering others devices.  
Another approach is to construct 3D functional tissues by layering 2D cell sheets.24, 25 This 
system allows for cell interconnection with gap junctions, resulting in electrically synchronous 
beating. Hamdi et al. recently compared such a bilayer myoblast cell sheet and a myoblast seeded 
collagen sponge.26 In both cases, significant improvements in left ventricular ejection fraction (LVEF) 
compared with the controls were reported but could not be related to the detectable persistence of the 
myoblasts at the studied time point neither to an increased cytokine production. Residual cells were 
more abundant in the patch-treated hearts than in those covered with the myoblast sheets and the 
authors suggested that the benefits of cell transplantation could be potentiated by an epicardial 
deposition of a pre-shaped cellularized patch. In their study, the number of MSC at the time of 
delivery was not assessed since myoblast sheets production required 7 days of culture.26 In another 
study, cells were embedded into a type I collagen matrix secured to heart with a fibrin sealant then 
cultured for 7 days. Despite high initial engraftment rates at 1 week, no hMSCs or residual patches 
were detectable at 4 weeks.27 Addition of bioactive factors could modify the scaffold to specifically 
recruit stem cells in the cardiac injury site.28 An injectable matrix metalloproteinase (MMP)- 
responsive, bioactive hydrogel was recently described as an in situ forming scaffold to deliver 
vascular cells derived from human embryonic stem cells (hESC).29 Tissue-engineered cardiac grafts 
were also prepared by using various biomaterials such as small intestine submucosa (SIS) 30 and 
biodegradable porous alginate scaffolds, cultured for 4 to 7 days before implantation.31 However, 
insufficient cell migration into scaffolds and inflammatory reaction due to scaffold biodegradation 
were reported. In comparison, our approach did not require any delay between seeding and 
implantation. Indeed, a fast infiltration of cells within the porous scaffold led to a cellularized patch 
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that could be implanted rapidly and seeded cells were thus evidenced here 1 and 2 months after 
scaffold implantation. A complete degradation of the scaffold was observed following implantation on 
infarcted tissue, but not on normal cardiac tissue. We have preliminary evidence of scaffolds degraded 
in vitro by leukocyte hydrolytic enzymes such as acid and alkaline phosphatase, as well as lysozyme, 
activities (unpublished results). Acid phosphatase and lysozyme have been shown to be more active in 
patients with acute myocardial infarction and might contribute to the in vivo degradation of 
scaffolds.32 This complete degradation of the scaffold that was observed within a month might have 
promoted the local engraftment and  survival of the  cells. 
 
In conclusion, we showed the feasibility to deliver MSCs to injured rat myocardium using a 
polysaccharide porous scaffold that improved engraftment in comparison with the most currently used 
approach of EC injection. Refinements of this approach, such as using injectable porous scaffolds 
containing appropriate molecules for cell differentiation or maintenance and sustained degradation 
profile may serve to enhance any benefits gained by cellular cardiomyoplasty.  
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TABLES 
 
Table 1: GFP+ cells in rat myocardium were analyzed by real-time RT-PCR one and two months after 
in vivo administration with endocardial injection (EC) or implantation of cellularized scaffold. Results 
were expressed as a median value of GFP+ cells (with range) and as a percentage of engraftment (n=5 
per condition). No significant difference was observed between groups. 
 
 1 month  2 months 
 EC Scaffold  EC Scaffold 
Residual cell number  
50 800      
(10700-61600) 
97 300      
(12300-167200) 
 
61 300       
(12400-87400) 
163 200        
(17500-2213000) 
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FIGURES CAPTION 
 
Figure 1: Polysaccharide-based scaffold. 
Macroscopic view of a dried porous scaffold (A, 6 mm diameter, 1 mm thickness). Porosity was 
evidenced with Environmental Scanning Electron Microscopy (B, scale bar 200 µm) and confocal 
microscopy observation of fluorescent FITC-dextran scaffold (C, scale bar 200 µm). Absorbance of 
MTT assay performed at day 1 after seeding rat bone marrow derived mesenchymal stem cells on 
porous scaffold as a function of the initial cell number. Non-cellularized porous scaffolds were used 
as blanks. Results are expressed as the mean value of the absorbance data +/- SEM (n=3). (D). Cells 
were observed as clusters in scaffold pores with light microscopy (E, 10x magnification). Cell 
viability within scaffold was confirmed with a live & dead assay. Bright green live cells were 
observed with a confocal microscope, whereas only few dead cells with compromised membranes 
fluoresce in red (F, scale bar 20µm). 
  
Figure 2: Implantation of scaffolds on rat heart. 
One month after implantation, scaffold on normal cardiac tissue was found intact (A, scaffold was 
stained with alcian blue for imaging purposes, scale bar: 2mm), as confirmed by fluorescent 
microscopic observation of heart sections showing cardiac tissue green autofluorescence and FITC-
labelled scaffold (B, scale bar 100 µm). In contrast, no scaffold could be identified macroscopically 
on infarcted cardiac tissue after one month (C, scale bar: 2mm) and only remnants of the FITC-
scaffold were seen embedded or integrated into the adjacent tissue on heart sections (D, scale bar 
100 µm). 
 
Figure 3: Cell transfer into myocardium. 
MSCs were characterized by their spindle shaped morphology, scale bar: 20 µm (A) together with the 
expression of CD90, CD29 and CD106 and lack of CD45 (B) and their capacity to differentiate (C) 
into osteogenic (top), chondrogenic (middle), and adipogenic (bottom) cell lineages (left, without 
induction; right, with induction).10 MSCs were lentivirally infected using a dual-promoter that 
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included GFP and PAC and transduced cells preserved their spindle-shaped morphology. scale bar: 
40 µm (D). Fluorescence emitted by a defined number of GFP+cells was used as calibrator for 
quantification of residual GFP+ cells in myocardium (E).  
 
Figure 4: Cell localization in infarcted area. 
Microscopic observation of green autofluorescent cardiac tissue (A) containing double-labelled 
PKH/BrdU cells one month after implantation of scaffold loaded with cells (scale bar : 1mm). (B) is a 
magnification of the infarcted area highlighted in A. Red PKH-labelled cells (C, scale bar : 1mm and 
D, scale bar : 50 µm) and BrdU-labelled cells were identified in the same area (D, with DAB staining, 
scale bar : 100 µm). GFP+ cells were identified in cardiac tissue 2 months after implantation of 
scaffold loaded with cells. Indirect immunohistofluorescence was performed with both Alexa 488-
anti-GFP and Alexa 594-anti-sarcomeric alpha-actinin (E). Original magnification 10x. 
  
Figure 5: Histology and RT-PCR analysis. 
(A) Typical appearance of the left ventricular scarred area. Haematoxylin/eosin (top row) and sirius 
red (bottom row) stained sections of heart tissue 2 months after implantation of scaffold loaded with 
cells (left column) or direct injection of cell suspension (right column). Scale bar 1 mm. (B) Fibrosis 
area was quantified by histomorphometric measurement on Sirius red stained sections and results are 
expressed as mean ± SEM (n=2 measurements for 3 animals in each group). (C) mRNA expression 
levels of matrix metalloproteases MMP-2, MMP-9 and vascular endothelial growth factor (VEGF) 
into myocardium were analyzed by real-time RT-PCR. Transcription factors mRNA levels, 
normalized against HPRT, UBC and Ywhaz as reference genes, were expressed as relative unit of 
averaged mRNA levels in myocardium of a control animal subjected to myocardial infarct but without 
cell administration. No effect was obtained with MMP-2 and MMP-9, but a significant increase of 
mRNA level for VEGF was observed at 2 months with the cellularized scaffold. *indicates a 
significant difference (p<0.05) 
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Figure 6: Functional assessment by echocardiography. 
Echocardiography was performed at 7 days and 2 months after myocardial infarction and results are 
presented as a percentage of day 7 value for animals having received either a control scaffold without 
cells, endocardial injection or a cellularized scaffold (n=9). LVFS: left ventricular fractional 
shortening (A); LVESD: left ventricular end systolic diameter (B). No significant difference was 
observed between groups. 
 






